A federal jury Monday night awarded bioscience company Elysium Health $2 million in its five-year battle with its former supplier ChromaDex, rejecting all trade secrets claims brought by ChromaDex while embracing Elysium’s counter-narrative about a plot by billionaire pharmaceutical investor Phil Frost.

Elysium is to pay ChromaDex nearly $3 million for breach of contract, which is the amount of the unpaid June 2016 supply agreement that triggered the five-year battle. Jurors also agreed that current Elysium Chief Product Officer Mark Morris breached his confidentiality agreement with ChromaDex, his ex-employer.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]